These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 35751657)
1. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML). Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657 [TBL] [Abstract][Full Text] [Related]
2. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report. Tollkuci E J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838 [TBL] [Abstract][Full Text] [Related]
3. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim M; Williams S Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051 [TBL] [Abstract][Full Text] [Related]
4. Midostaurin for the treatment of acute myeloid leukemia. Patnaik MM Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444 [TBL] [Abstract][Full Text] [Related]
5. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. Stansfield LC; Pollyea DA Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600 [TBL] [Abstract][Full Text] [Related]
6. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831 [TBL] [Abstract][Full Text] [Related]
7. Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia. Schlafer D Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365750 [No Abstract] [Full Text] [Related]
9. Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. Menna P; Salvatorelli E; Del Principe MI; Perrone S; Pagano L; Marchesi F; Minotti G Chemotherapy; 2021; 66(1-2):47-52. PubMed ID: 33677444 [TBL] [Abstract][Full Text] [Related]
10. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824 [TBL] [Abstract][Full Text] [Related]
11. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261 [TBL] [Abstract][Full Text] [Related]
12. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Luskin MR; DeAngelo DJ Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942 [TBL] [Abstract][Full Text] [Related]
13. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134 [TBL] [Abstract][Full Text] [Related]
15. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457 [TBL] [Abstract][Full Text] [Related]
16. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive. Garcia JS; Percival ME Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055 [TBL] [Abstract][Full Text] [Related]
17. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3. Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594 [TBL] [Abstract][Full Text] [Related]
19. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis. Galinsky I; Coleman M; Fechter L Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]